Exclusive Online Content
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines
Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….
COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron & Delta Variants of SARS-CoV-2
Ocugen, Inc.and its partner, Bharat Biotech recently announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine….
atai Life Sciences Announces FDA IND Clearance for PCN-101 R-ketamine Program
atai Life Sciences N.V. recently announced the US FDA has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the….
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
Sana Biotechnology, Inc., IASO Biotherapeutics, and Innovent Biologics recently announced the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct for use in certain….
NeoCura & PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics
NeoCura Bio-Medical Technology Co., Ltd. and PhoreMost Limited recently announced an oncology drug discovery research collaboration. As part of the collaboration, PhoreMost’s SITESEEKER phenotypic screening platform and NeoCura’s full-process RNA drug design platform will….
Malvern Panalytical Expands Pharmaceutical Drug Development Solutions Through Acquisition of Creoptix
Malvern Panalytical recently announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to….
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
4D Molecular Therapeutics recently announced the US FDA has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in….
Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide
Starton Therapeutics Inc. recently announced it has received a Clinical Trial Authorization (CTA) in the Netherlands to initiate a Phase 1 study evaluating STAR-LLD bioavailability in….
Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer
Veru Inc. recently announced the US FDA has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm, a selective androgen receptor targeting agonist, for the treatment of….
Adare Pharma Solutions Announces Appointment of Tom Sellig as Chief Executive Officer
Adare Pharma Solutions recently announced the appointment of Tom Sellig as Chief Executive Officer (CEO). Sellig, a 30-year veteran of the pharmaceutical and life sciences industries, will lead the….
Univercells Acquires SynHelix, Entering Into Synthetic Biology & the Race to Next-Generation DNA Synthesis
Univercells S.A. (Univercells) recently announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable, and….
Sosei Heptares & Verily to Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases
Sosei Group Corporation and Verily recently announced they have entered into a strategic research collaboration. The research agreement brings together the….
AVITA Medical Establishes Proof-of-Concept for Novel Treatments Using Genetically Modified Skin Cells
AVITA Medical, Inc. recently announced that preclinical data successfully established proof-of-concept in two key areas of cell-based gene therapy – skin rejuvenation and….
Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines From AstraZeneca
Covis Pharma Group recently announced Covis Pharma GmbH has completed the acquisition of Eklira (aclidinium bromide), known as Tudorza in the US and marketed as Bretaris in some countries, and….
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
MannKind Corporation recently announced that has extended its collaboration with Thirona Bio, Inc. with the purchase of a second convertible note issued by Thirona, and the appointment of….
Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Pfizer Inc. and BioNTech SE recently announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles….
Rain Therapeutics & Roche to Collaborate on Clinical Trial of Milademetan Combination With Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
Rain Therapeutics Inc. recently announced a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab…..
Cue Biopharma & LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102
Cue Biopharma, Inc. and LG Chem Life Sciences recently announced a key milestone in the selection of a clinical product candidate has been reached in their collaboration for CUE-102, an Immuno-STAT biologic, jointly developed to….
Curia Unveils Comprehensive mRNA Solution
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, recently unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through….
Santhera Enters Exclusive License Agreement With Sperogenix for Vamorolone in Rare Diseases in the Greater China Region
Santhera Pharmaceuticals recently announced it has entered into an exclusive license agreement with Sperogenix Therapeutics, a China-based company specializing in orphan diseases. Under this agreement….
